nanotehnoloogia, nanoteknologia, nanotechnologija, nanotehnologijas, nanoteknologija,
nanotechnologii, nanotecnologia, nanotehnologijo, nanoteknik
Nano Geneeskunde...Nano Medicína
of blood glucose for diabetes patients
Eyesense and Capsulution sign development contract
Berlin, 30.06.2006 - The swiss company Eyesense AG
and the Berlin based Capsulution Nanoscience AG have
recently signed a development contract aiming at
the development of innovative and more user friendly
products for diabetes patients to monitor blood sugar
These products for a pain free and more reliable measurement of blood sugar
levels are being developed under the direction of Eyesense AG. “The new product
eases the procedure for frequent blood glucose level measures and helps diabetes
patients to control and maintain healthy blood glucose levels.”, said Dr. Peter
Herbrechtsmeier, CEO of Eyesense. Thereby common sequela of diabetes, for example
cardiovascular disease or loss of sight, can be reduced.
Both companies count on their long experience in joint developmental work.
Capsulution makes a major contribution to the product by taking advantage of
its tunable nano-capsules. The biocompatible capsules ensure the measurement
of the blood glucose near the human eye. The frequent measurement of the blood
sugar concentration is performed by a special portable measuring instrument
developed by Eyesense.
About Eyesense AG:
EyeSense AG is a venture-backed diagnostic device company based in Basel and
operations close to Frankfurt a. Main, Germany. Eyesense was founded in 2006
as a spin-out from Ciba Vision AG (a Novartis company) and develops ophthalmic
diagnostic systems focusing on glucose testing for diabetic patients. In addition
to glucose, the testing platform being developed by Eyesense has the potential
to measure a broad variety of medical-relevant analytes in patients.
Herr Dipl.-Kfm. Alexander Herrmann
Telefon: +49 (0)30-63 92 36 00
Fax: +49 (0)30-63 92 36 01
Herr Dr. Peter Herbrechtsmeier
Telefon: +49 (0) 6022 942120
Über Capsulution NanoScience AG: Capsulution NanoScience AG is a leading
nanotechnolopy company focusing on the development of tailor-made drug delivery
systems and other innovative life science products based on tunable nano-sized
capsules. The company applies its worldwide-patented so-called LBL-Technology®.
Based on their minute size, their functionality and their highly reproducible
production process the tunable capsules can be used for a multitude of different
applications. Accordingly, the precisely sized capsules can be made to function
in a manner to suit the intended application, and can be given the appropriate
biochemical, electrical, optical and magnetic properties as required by the customer.
In order to meet customers needs for complete product solutions Capsulution has
recently designated a Japanese licensee as the preferred developer, manufacturer
and distributor for automated LBL-units. Only six month after the signing of
the licence agreement, EBARA has started operation of the first prototype plant
(LBL-Unit®) for the manufacture of Capsulution's LBL capsules. In 2005, renowned
growth consultants Frost & Sullivan have awarded the year's “Product Differentiation
Innovation Award” in the global nanobiotechnology market to Capsulution NanoScience
AG, Berlin. The company has received the award for the innovative and diverse
use of their proprietary nanobiotechnology product platform, which can be implemented
in various life sciences applications.
story has been adapted from a news release
Diese Meldung basiert auf einer Pressemitteilung -
tekst is gebaseerd op een nieuwsbericht -
the wave ?
some news ?
click on archive photo
how about joining us
contacting us ?